{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:18Z","timestamp":1790810058434,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neurol.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:22:06Z","timestamp":1761355326000},"page":"1008-1014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-term follow-up of anti-MAG neuropathy patients given bendamustine plus rituximab combination therapy"],"prefix":"10.1016","volume":"181","author":[{"given":"N.","family":"Bezou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2954-6743","authenticated-orcid":false,"given":"B.","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-8180","authenticated-orcid":false,"given":"E.","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4602-2681","authenticated-orcid":false,"given":"P.","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-8090","authenticated-orcid":false,"given":"C.","family":"Tard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2025.09.009_bib0150","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2025.09.009_bib0155","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force\u2014Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0160","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2025.09.009_bib0165","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2025.09.009_bib0170","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.clinph.2018.07.021","article-title":"Anti-MAG neuropathy: role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels","volume":"129","author":"Garg","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1529-8027.2010.00278.x","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.neurol.2025.09.009_bib0180","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"Leger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.09.009_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jns.12156","article-title":"Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study: long-term efficacy of rituximab in IgM","volume":"21","author":"Iancu Ferfoglia","year":"2016","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.neurol.2025.09.009_bib0190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.18202","article-title":"Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: a report of 64 patients","volume":"198","author":"Nivet","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","article-title":"Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-na\u00efve patients","volume":"60","author":"Buske","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0200","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.26796","article-title":"Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Gertz","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0205","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00415-023-12068-4","article-title":"Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy","volume":"271","author":"Gu\u00e9r\u00e9my","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0210","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2025.09.009_bib0215","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0220","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41375-022-01762-3","article-title":"Diagnostics in Waldenstr\u00f6m's macroglobulinemia: a consensus statement of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia","volume":"37","author":"Dogliotti","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.neurol.2025.09.009_bib0225","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ajh.26210","article-title":"Assessment of fixed-duration therapies for treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia","volume":"96","author":"Abeykoon","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2025.09.009_bib0230","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features","volume":"89","author":"Svahn","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.09.009_bib0235","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.0954-6820.1983.tb08613.x","article-title":"Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms","volume":"214","author":"Steen","year":"1983","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.neurol.2025.09.009_bib0240","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale","volume":"77","author":"Graham","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2025.09.009_bib0245","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1212\/WNL.41.6.799","article-title":"The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests","volume":"41","author":"Dyck","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.09.009_bib0250","first-page":"2016","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2025.09.009_bib0255","first-page":"353","article-title":"Les autoanticorps IgM anti-MAG par Elisa B\u00fchlmann\u00a0: apport diagnostique dans 117 neuropathies p\u00e9riph\u00e9riques auto-immunes associ\u00e9es \u00e0 une IgM monoclonale \u00e0 activit\u00e9 anti-SGPG\/SGLPG","volume":"64","author":"Caudie","year":"2006","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.neurol.2025.09.009_bib0260","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berck","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2025.09.009_bib0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2014.06.041","article-title":"Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials","volume":"344","author":"Suanpraset","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2025.09.009_bib0270","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2025.09.009_bib0275","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1212\/WNL.54.4.943","article-title":"Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group","volume":"54","author":"Merkies","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.09.009_bib0280","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.clml.2016.04.004","article-title":"Anti-myelin-associated-glycoprotein antibody peripheral neuropathy response to combination chemoimmunotherapy with bendamustine\/rituximab in a patient with biclonal IgM \u03ba and IgM \u03bb: case report and review of the literature","volume":"16","author":"Gomez","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.neurol.2025.09.009_bib0285","doi-asserted-by":"crossref","first-page":"116777","DOI":"10.1016\/j.jns.2020.116777","article-title":"Bendamustine\u2013rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy","volume":"413","author":"Massa","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2025.09.009_bib0290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mus.27954","article-title":"Anti-myelin-associated glycoprotein neuropathy: where do we stand?","volume":"68","author":"Stino","year":"2023","journal-title":"Muscle Nerve"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725006162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725006162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:33:58Z","timestamp":1765413238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725006162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0035378725006162"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.09.009","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term follow-up of anti-MAG neuropathy patients given bendamustine plus rituximab combination therapy","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}